![My [gs]](/images/basic/my_gs_logo.gif){kind=logo}
Agilent Technologies Inc.. (1/11/10). "Press Release: Institute for Medical Immunology Adopts Agilent Technologies’ Electronic Lab Notebook". Santa Clara, CA & Charleroi.
 |
Region | Belgium |
 |
Organisation | Université Libre de Bruxelles (ULB) |
| Organisation 2 | Agilent Technologies Inc. (NYSE: A) | |
| Group | Agilent (Group) | |
 |
Product | electronic laboratory notebook (ELN) (software) |
 |
Index term | supply (of product/service) |
"The IMI subjected competitive systems to rigorous evaluation, and we're very delighted that their scientists doing the testing unanimously selected the Agilent ELN," said Debra Toburen, Agilent senior product manager, Informatics.
"The Agilent ELN provides the perfect set of tools for organizing the large amounts of data generated by our scientists," said Dominique Demonté, deputy director of the IMI. "It also will be helpful in the application of our internal intellectual property policy. We based our purchase decision largely on the Agilent system's ease-of-use, architecture and also on the level of support provided by the Agilent team."
The Agilent ELN is designed to provide benefits beyond eliminating paperwork. Its scalable, integrated platform simplifies and accelerates the R&D process by facilitating collaboration in a secure framework. Researchers can easily search, retrieve and share data using the ELN's Web interface.
About The IMI
Located on the BIOPARK Charleroi Brussels South, the IMI is part of the Faculty of Medicine of the ULB. Work focuses on translating discoveries "from bench to bedside" based on multidisciplinary teams of medical doctors and basic scientists. Projects are organized along four research programs addressing key questions in medical immunology: vaccine adjuvants, the immune system in early life, transplantation medicine, and immune biomarkers. Through its participation in several research networks, it is expected to contribute to the development of Wallonia in the context of the European Research Area.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 17,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.
# # #
Contact:
Stuart Matlow, Agilent
+1 408 553 7191
stuart_matlow@agilent.com
Oberdan Leo, ULB
+32 2 650 9560
oleo@ulb.ac.be
Record changed: 2010-07-21 |
More documents for Université Libre de Bruxelles (ULB)
- [1] Ipsogen SAS. (1/28/08). "Press Release: Ipsogen Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis and Treatment Decision". Marseille....
- [2] Euroscreen S.A.. (4/26/06). "Press Release: Euroscreen Awarded European Patent on P2Y13 (GPR86) Receptor". Brussels....
- [3] Euroscreen S.A.. (11/9/05). "Press Release: Euroscreen Strengthens its Patent Position in the Field of Inflammatory Targets". Brussels....
- [4] Euroscreen S.A.. (9/14/04). "Press Release: Euroscreen Announces US Patent on Human P2Y4 Receptor". Brussels....
- [5] Euroscreen S.A.. (6/30/04). "Press Release: Euroscreen Receives Key Patent for Purinenergic Receptor. Euroscreen Announces European Patent on Human P2Y4 Receptor". Brussels....
- [6] Euroscreen S.A.. (3/9/04). "Press Release: Euroscreen Awarded US Patent Covering Screening Methods Using SHIP2, an Emerging Target for the Treatment of Type 2 Diabetes Mellitus. Screening Methods Using Src-Homology Inositol Phosphatase-2 (SHIP2)". Brusse...
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
» top